On 8 April, the CEOs of the pharmaceutical industry issued a warning to the President of the European Commission, Ursula von der Leyen: unless Europe rapidly introduces radical policy changes, there is an increasing risk that pharmaceutical research, development and manufacturing will be redirected to the United States, according to the European Federation of Pharmaceutical Industries and Associations (EFPIA).
A survey of EFPIA members revealed that up to 85% of capital expenditure...